

Opinion Paper

Damien Gruson*, Bernard Guget, Woonchang Lee, Mercy Thomas, Lindsay Mackay, Lianna Kyriakopoulou, James H. Nichols, He Sarina Yang, Andrew South, Elie Fux, Sanja Stankovic, Sharon Geaghan, Larry Kricka, Michele Paque, Yan Liu, Sven Ebert, Ronda Greaves and Swarup Shah

Laboratory medicine 2050: from testing to health intelligence network, a vision from the IFCC Emerging Technologies Division

<https://doi.org/10.1515/cclm-2026-0903>

Received June 8, 2026; accepted July 9, 2026;

published online July 27, 2026

Abstract: Laboratory medicine is undergoing a profound transformation driven by advances in artificial intelligence (AI), automation, and data interoperability. By 2050, laboratories may evolve from analytical testing facilities into an interconnected health intelligence capable of translating biological, digital, and environmental data into more personalized, preventive, and sustainable healthcare solutions. Building on previous foresight analysis conducted by the IFCC Emerging Technologies Division (ETD), global healthcare outlook reports, and expert-informed horizon

scanning, this paper explores ten megatrends that may shape laboratory medicine by mid-century. These include precision multi-omics, AI-supported diagnostics, distributed healthcare models, patient-owned data ecosystems, digital twins, convergence of imaging and laboratory medicine, population-wide prevention strategies, regenerative therapies, sustainability imperatives, and workforce transformation. Collectively, these developments represent a paradigm shift from data generation to data interpretation, positioning laboratories as trusted nodes within the health intelligence network connecting patients, clinicians, and healthcare systems. The integration of automation with advanced multi-omics technologies, including robotic liquid

***Corresponding author: Damien Gruson**, Department of Clinical Biochemistry, Cliniques Universitaires St-Luc, Belgium and UCLouvain, Brussels, Belgium; Pôle de recherche en Endocrinologie, Diabète et Nutrition, Institut de Recherche Expérimentale et Clinique, Cliniques Universitaires Saint-Luc and UCLouvain, Brussels, Belgium; IFCC Division on Emerging Technologies, Milan, Italy; and Department of Laboratory Medicine, Cliniques Universitaires St-Luc and UCLouvain, 10 Avenue Hippocrate, Brussels, 1200, Belgium, E-mail: damien.gruson@uclouvain.be

Bernard Guget, IFCC Division on Emerging Technologies, Milan, Italy; and National Committee for the Selection of Reference Laboratories, Ministry of Health, Paris, France. <https://orcid.org/0000-0002-8010-1404>

Woonchang Lee, IFCC Division on Emerging Technologies, Milan, Italy; and Department of Laboratory Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea

Mercy Thomas, Murdoch Children's Research Institute, The Swinburne University of Technology, Melbourne, VIC, Australia

Lindsay Mackay, IFCC Division on Emerging Technologies, Milan, Italy; and National Measurement Institute, Lindfield, NSW, Australia

Lianna Kyriakopoulou, IFCC Division on Emerging Technologies, Milan, Italy; and Hospital for Sick Children, Toronto, ON, CA, USA

James H. Nichols, IFCC Division on Emerging Technologies, Milan, Italy; and Department of Pathology, Microbiology, and Immunology Vanderbilt University School of Medicine, Nashville, TN, USA

He Sarina Yang, IFCC Division on Emerging Technologies, Milan, Italy; and Weill Cornell Medicine, New York, NY, USA

Andrew South, IFCC Division on Emerging Technologies, Milan, Italy; and Department of Genetic Disease and Cancer Biology, Wisconsin Institute of Medical Research, Madison, WI, USA

Elie Fux, IFCC Division on Emerging Technologies, Milan, Italy; and Roche Diagnostics Penzberg, Penzberg, Germany

Sanja Stankovic, IFCC Division on Emerging Technologies, Milan, Italy; and Center for Medical Biochemistry, University Clinical Center of Serbia, Belgrade, Serbia

Sharon Geaghan, IFCC Division on Emerging Technologies, Milan, Italy; and Departments of Pathology, Stanford University School of Medicine, Stanford, CA, USA

Larry Kricka, IFCC Division on Emerging Technologies, Milan, Italy; and Department of Pathology and Lab. Medicine, University of Pennsylvania Medical Center, Pennsylvania, PA, USA

Michele Paque, PricewaterhouseCoopers Belgium, Diegem, Belgium

Yan Liu, IFCC Division on Emerging Technologies, Milan, Italy; and Medical and Scientific Affairs Mindray Bio-Medical Electronics, Guangdong, China

Sven Ebert, IFCC Division on Emerging Technologies, Milan, Italy; and Core Workflow Research and Early Development, Roche Diagnostics International, Rotkreuz, Switzerland

Ronda Greaves, IFCC Division on Emerging Technologies, Milan, Italy; Victorian Clinical Genetics Services Murdoch Children's Research Institute, Parkville, VIC, Australia; and Department of Paediatrics, Melbourne Medical School, University of Melbourne, Parkville, VIC, Australia

Swarup Shah, IFCC Division on Emerging Technologies, Milan, Italy; and Department of Laboratory Medicine, P. D. Hinduja Hospital and Medical Research Centre, Mumbai, India

handling, autonomous LC-MS/MS platforms, spatial proteomics, and real-time metabolomics, will accelerate the transition toward precision and planetary health. Four exploratory scenarios illustrate plausible trajectories for laboratory medicine in 2050. The Hyper-Intelligent Laboratory explores the implications of self-learning systems and advanced analytics capable of supporting earlier disease prediction and intervention. The Sustainable and Regenerative Laboratory illustrates how environmental stewardship and diagnostic excellence may converge within circular healthcare ecosystems. The Patient-in-the-Loop Revolution examines a future in which citizens become active stewards of their health data and participants in healthcare decision-making. The Spacefaring Laboratory extends this reflection beyond Earth, illustrating how extreme environments may accelerate innovation in autonomous diagnostics, sustainability, and human health monitoring. By 2050, laboratory medicine could serve as a central intelligence layer within healthcare systems, transforming biological signals into actionable knowledge. Achieving this vision will require scientific innovation, regulatory adaptability, equitable access, ethical governance, sustainability, and a future-ready workforce.

Keywords: laboratory medicine; artificial intelligence; precision health; decentralized diagnostics; multi-omics; digital twin

Opening Vignette – A Day in 2050

Milan, Italy, spring 2050.

Anna, 68, wakes to the soft chime of her home health hub. Overnight, her wearable patch collected biochemical, metabolic, and physiological data. A small capillary point-of-care testing (POCT) device on her kitchen counter automatically processed a panel of renal, cardiac, and inflammatory markers while she slept.

Her digital twin, a continuously updated simulation of her physiology, has just run 1.2 million therapeutic scenarios in the cloud. An algorithm detects subtle signs of early renal fibrosis. Within seconds, Anna's core laboratory node at the hospital receives the flagged data, automatically validated against her lifelong biomarker passport.

A lab-based AI suggests targeted nutraceutical intervention and minor medication adjustment. Her nephrologist approves the plan remotely. As Anna prepares breakfast, her health hub notifies her that her updated medication is already on the way. Minutes later, a small delivery drone lands briefly on her balcony, leaving a sealed package approved and

tracked by the laboratory system. This seamless, closed-loop system, from continuous biosensing and AI-driven diagnosis to automated therapeutic delivery, ensures timely, personalized intervention. By the time Anna sits down for breakfast, she has already received a message: "Good morning, Anna, your kidneys are stable. Let's keep it that way."

Although speculative, this vignette extrapolates from technological and organizational trends already emerging in healthcare.

Introduction

Laboratory medicine has always been shaped by the scientific and societal transformations of its era [1, 2]. From the first biochemical assays to the era of automation and artificial intelligence (AI), the discipline has continually reinvented itself to serve the evolving needs of healthcare. Yet the pace and scale of change entering the mid-21st century are unprecedented. By 2050, demographic, technological, ecological, and ethical forces are likely to converge in ways that could redefine the identity of the clinical laboratory, transforming it from a testing service into a decentralized, data-centric health intelligence network capable of sensing, interpreting, and acting across the continuum of care.

As demographic projections show, the world will exceed nine billion inhabitants by mid-century, with more than two billion people over 60 years of age [3]. Chronic diseases, climate stress, and economic constraints will strain healthcare infrastructures. Simultaneously, continuous biosensing, nanotechnology, and AI-driven analytics will blur the boundaries between clinical, environmental, and personal health data. Within this dynamic equilibrium, laboratory medicine may need to evolve from producing test results toward generating trusted and actionable intelligence, linking molecular events to population outcomes and human biology to planetary resilience. The foundations of this transformation were already laid in the early 2020s. The IFCC Emerging Technologies Division (ETD) identified a set of "key questions about the future of laboratory medicine" spanning the big picture of healthcare, pre-analytical, analytical, and post-analytical evolution, and the relationships that sustain value creation [3]. Those questions anticipated a patient-centered, digitally integrated ecosystem shaped by automation, omics, and sustainability. Today, that foresight provides a roadmap to the next frontier: laboratories as orchestrators of intelligent, preventive, and planetary health systems.

Concurrently, broad-based foresight initiatives across medicine, life sciences, and healthcare systems point to converging megatrends. Reports envision healthcare in 2050 as

personalized, AI-enabled, preventive, and seamlessly interoperable, where genetic and environmental data continuously inform targeted interventions and wellness-first policies [4]. Futurologists of the PharmiWeb 2050 initiative and the Artificial Intelligence Medical and Engineering Researchers Society (AIMERS) foresee the pervasive integration of AI, quantum computing, and regenerative medicine, transforming diagnosis, drug discovery, and patient engagement [5].

The BMJ Commission on the Future of Academic Medicine has called for a realignment of science, ethics, and equity with planetary health imperatives [6]. Collectively, these perspectives converge toward a single paradigm shift: healthcare as a distributed, intelligent network where data are the new bloodstream and laboratories the neural nodes that ensure coherence, quality, and meaning.

Foresight methodology

This vision paper was developed by members of the IFCC Emerging Technologies Division (ETD) using a narrative foresight approach. The ten megatrends presented in this manuscript were identified through the integration of multiple information sources, including previous ETD foresight initiatives, published scientific literature, global healthcare outlook reports, technology trend analyses, and expert discussions conducted within the Division.

Rather than representing predictions, the proposed megatrends and scenarios should be interpreted as plausible future trajectories intended to stimulate discussion, strategic reflection, and long-term planning. The four scenarios were constructed by combining key technological, societal, environmental, demographic, and healthcare drivers expected to influence laboratory medicine over the next twenty-five years.

This approach aligns with established horizon-scanning and foresight methodologies frequently used in healthcare, innovation management, and public policy to explore uncertainty and support preparedness for alternative futures.

Aim of the paper

This paper aims to explore plausible horizons for laboratory medicine by 2050 and to stimulate discussion regarding the future role of laboratories within increasingly interconnected healthcare ecosystems. This vision is not merely technological, it is strategic, societal, and moral. As such, this 2050 horizon requires the reimagining of governance, education, sustainability, and equity to ensure that the

analytical precision of laboratory medicine translates into global well-being. To achieve this, we first examine the changing global landscape of health that makes this transition both necessary and urgent. We then outline the ten megatrends shaping the future of laboratory medicine, and finally, we present four plausible scenarios that illustrate how different combinations of technological innovation, societal choices, regulatory frameworks, and environmental priorities could shape laboratory medicine by mid-century.

A note on uncertainty

The future developments discussed in this paper should not be interpreted as forecasts. Technological innovation, societal acceptance, economic constraints, geopolitical developments, and regulatory evolution will ultimately determine the extent to which these trajectories materialize. The scenarios presented are therefore intended as exploratory tools rather than predictive statements, helping laboratory professionals and healthcare stakeholders prepare for multiple possible futures.

The changing landscape of health

By 2050, the global health landscape will be profoundly reshaped by demographic ageing, chronic disease expansion, environmental stress, and widening inequities. The convergence of climate change, urbanization, geopolitical instability, and technological acceleration will challenge the foundations of public health. For laboratory medicine, this landscape defines both the scale of the challenge and the scope of the opportunity: to evolve from a reactive analytical service into a predictive, planetary, and equitable intelligence network capable of sensing biological and ecological signals across individual, population, and environmental scales.

Demography and disease burden

Life expectancy is expected to continue increasing over the coming decades, although gains in healthy life expectancy may remain more limited. The Global Burden of Disease forecasts an unprecedented rise in chronic, degenerative, and metabolic conditions driven by population ageing, urbanization, and lifestyle transitions [7, 8].

Metabolic and cardiovascular diseases are likely to remain among the dominant global health challenges of the

21st century [8, 9]. By 2050, more than 3.8 billion adults will live with overweight or obesity, representing over half of the world's adult population, driving exponential increases in diabetes, cardiovascular disease, and cancer incidence. The American Heart Association projects that 61 % of U.S. adults will be hypertensive and 27 % diabetic by mid-century [10]. Without systemic preventive action, up to 6.5 billion years of life could be lost due to obesity-related premature deaths and 2.8 trillion USD in annual GDP by 2050 [9]. Continuous biomarker monitoring, remote testing, and metabolic phenotyping may increasingly position laboratory medicine as a key contributor to earlier identification and intervention.

Despite decades of therapeutic progress, cardiovascular disease will remain the leading global cause of mortality with rising prevalence of coronary artery disease, atrial fibrillation, and heart failure, especially in ageing and low-income populations [10, 11]. Predictive biomarkers and AI-supported risk stratification could become increasingly important tools.

Meanwhile, neurodegenerative diseases will surge in parallel. The Global Burden of Disease Dementia Forecasting Study estimates a rise from 57 million people with dementia in 2019 to 153 million by 2050, largely due to population ageing and modifiable risk factors such as obesity, diabetes, and air pollution [7]. Blood-based biomarkers for early neurodegeneration including phosphorylated tau and neurofilament light chain will become foundational tools for population-scale screening and intervention, transforming the laboratory's role into a disease area that has historically lacked actionable early diagnostics [12].

Cancer, too, will expand sharply. JAMA Network Open projects a 77 % increase in new cases, reaching 35 million new cases and 18 million deaths annually by 2050, with the steepest rises in low-HDI (Human Development Index) regions where access to diagnostics and prevention remains limited [13]. In addition to this the incidence of cancer in younger individuals, particularly GI and oral cancers, are on the rise, bringing the burden of disease into a younger generation [14, 15]. Laboratory medicine will therefore be pivotal for equitable screening, molecular diagnostics, and precision oncology.

Expanded newborn and prenatal screening will fundamentally alter the individual experience of disease risk across the life course. Individuals are likely to know about these adult conditions from a young age. Neonatal (and prenatal) screening programs will have expanded beyond the traditional definition to encompass thousands of conditions though genomic screening [16, 17]. This expanded access to genomic information may confer both the benefits

and burdens associated with early knowledge of future health risks. A more precise understanding of the continually evolving immune system, combined with an expanding array of immunomodulating therapies, may provide unprecedented opportunities. Patient immunotypes, refined through AI-supported longitudinal monitoring, could help predict intervention-specific outcomes and guide clinical options [18].

Finally, antimicrobial resistance (AMR) continues to threaten modern medicine. The Lancet AMR study projects 8 million annual deaths by 2050, with the largest increases among older adults [19]. The growing mismatch between antibiotic innovation and microbial evolution highlights the growing need for laboratory-based surveillance and global data sharing.

Climate, pandemics, and planetary health

Climate change has become an increasingly important determinant of health outcomes across populations [20]. Rising temperatures, biodiversity loss, and pollution are expected to amplify cardiometabolic, respiratory, and infectious diseases. By 2050, the Capital Economics and World 2050 analyses predict a global average surface temperature increase of 1.8 °C, with profound social and economic repercussions [20]. Air pollution already ranks among the top five risk factors for mortality and is projected to exacerbate dementia and cardiovascular outcomes [7, 21].

Environmental degradation will accelerate zoonotic spillover, antimicrobial resistance spread, and vector-borne epidemics. Lessons from COVID-19 and emerging pathogens highlight that pandemics are not rare events but systemic consequences of ecological imbalance and global connectivity. A more coordinated international governance approach led by a legal framework supported by integrated activities from animal welfare groups and international health organizations will lead to removal of the underlying drivers of zoonotic diseases [22]. In this scenario, clinical laboratories may progressively evolve from reactive testing hubs toward sentinel ecosystems capable of supporting proactive surveillance activities that play a proactive role in monitoring of zoonotic disease drivers to prevent future pandemics globally, integrating pathogen genomics, wastewater surveillance, and real-time health intelligence across continents. Planetary health frameworks further emphasize the need to monitor both human and environmental indicators, recognizing the close interdependence between ecosystem integrity and human health.

Inequities and the economics of health

Significant geographic disparities in disease burden are likely to persist and may intensify by 2050. By mid-century, cancer mortality could triple in low-HDI nations compared with only a 40 % increase in high-HDI countries [13]. Similar disparities are anticipated for cardiovascular and metabolic diseases [10, 11]. The World 2050 New Economic Order report predicts continued concentration of wealth in high-income countries despite demographic shifts [8]. In contrast, the burden of disease will grow fastest in low- and middle-income regions, where climate vulnerability, population growth, and healthcare access gaps intersect [13, 23]. If unchecked, health expenditure may exceed 20 % of GDP in several advanced economies by 2050, while many emerging economies remain under-resourced [24, 25].

These inequities may become one of the defining challenges for future healthcare systems. This growing imbalance emphasizes the need for value-based diagnostics, where laboratory intelligence guides prevention, personalization, and sustainability rather than volume of testing. AI models should be trained on datasets reflecting biological and ancestral diversity across global populations. Reference intervals, biomarker thresholds, and clinical decision algorithms should be validated.

The future described in this paper should not be viewed exclusively through the lens of high-income countries. Many of the innovations discussed, including decentralized diagnostics, affordable point-of-care testing, AI-assisted interpretation, cloud-based interoperability, and digitally connected laboratory networks, have the potential to accelerate universal access to high-quality laboratory medicine in low- and middle-income countries. Realizing this opportunity, however, will require equitable financing, investment in workforce capacity, locally relevant validation, sustainable digital infrastructure, and proportionate regulatory frameworks. Without these enabling conditions, technological innovation risks widening rather than reducing global health inequalities.

Synthesis

By 2050, laboratory medicine will operate within a healthcare landscape shaped by demographic ageing, chronic disease, environmental change, and widening global inequities. These converging pressures will require laboratories to move beyond analytical testing toward generating trusted health intelligence that supports prevention, personalization, and sustainability (Figure 1). Future progress will depend not only on technological innovation but

also on equitable implementation, workforce development, and responsible governance. Predictive diagnostics without equitable access risk widening health disparities, while planetary health surveillance without global collaboration remains incomplete. Together, these demographic, environmental, economic, and societal forces provide the rationale for the ten megatrends described below, illustrating how laboratory medicine may progressively evolve into a connected health intelligence network supporting individuals, populations, and planetary health.

Ten megatrends in laboratory medicine

The following ten megatrends describe ongoing or emerging shifts that may progressively reshape laboratory medicine by 2050, depending on the pace of technological innovation, regulatory adaptation, healthcare system readiness, and societal acceptance.

Precision diagnostics, integrated multi-omics, and automation

Consider what a routine clinical encounter might involve by 2050. The era of precision diagnostics is likely to be characterized by the increasing integration of genomics, proteomics, metabolomics, lipidomics, microbiome profiling, and exposome analysis into clinical decision-making. By 2050, multi-omics will move from research laboratories to everyday medicine, enabling a new generation of composite biomarker panels that inform both prevention and therapy [26].

An important aspect of the evolving field is the incorporation of the “Exposome”, that is, all environmental exposures (including pollutants, diet and lifestyle) that interact with an individual’s biology across time [27]. A simple blood sample could reveal genetic predisposition, metabolic pathways, immune status, and environmental exposure in a unified molecular fingerprint. This integration will not only transform disease detection but also enable real-time health navigation, continuously updating a person’s biological map throughout life.

This integration will be accelerated by advances in high-throughput proteomics and clinical metabolomics, enabling the simultaneous detection of thousands of proteins and metabolites per sample, with increasing accessibility thanks to emerging automated workflows [28–30]. Automation-driven multi-omics integration will be key: the convergence




Figure 1: Laboratory medicine 2050: from testing service to health intelligence network. The figure depicts the shift from a linear “sample–analysis–report” model to a circular, data-driven health intelligence network powered by AI, multi-omics, interoperability, and sustainability. By 2050, laboratories evolve into interconnected, predictive, and ethical nodes linking patients, clinicians, and environmental systems within a real-time health intelligence network.

of robotic work cells, hyperautomation, and federated AI systems, defined as distributed machine learning approaches that train algorithms across multiple decentralized data sources without transferring sensitive data, will transform laboratories into integrated bioanalytical platforms capable of generating and contextualizing complex molecular data within minutes. As demonstrated during the COVID-19 pandemic, large-scale molecular workflows can be scaled autonomously with robotic platforms to meet surging demand and ensure biosafety. By 2050, fully automated LC-MS/MS, digital PCR, and single-cell omics could become part of routine core laboratory instrumentation, enabling laboratories to be both the backbone and the brain of health intelligence networks [31, 32].

Emerging molecular and POCT technologies may substantially improve the speed, sensitivity, and accessibility of pathogen detection and monitoring. The optimization of POCT through emerging technologies (multiplex detection, single-base resolution) will cut down mortality rates and will reduce costs [33].

Furthermore, the democratization of cost-efficient technologies will facilitate the continuous acquisition of longitudinal data at the individual level. By moving away from static population averages, laboratories will establish personalized reference intervals, dynamic ‘biological baselines’ that significantly reduce misdiagnosis by detecting subtle deviations unique to a patient’s physiology. On a macro scale, improved standardization of these diagnostic outputs will enable the aggregation of real-time epidemiological data. This global data liquidity will benefit bio-surveillance programs (e.g., the early detection of localized disease outbreaks) and public health resource allocation, allowing authorities to track the efficacy of environmental interventions or vaccination campaigns with unprecedented granular precision. Spatial omics and transcriptomic profiling could generate dynamic molecular maps of disease

progression and treatment response, including at single-cell resolution [34, 35]. Whole blood transcriptomics are already revealing systemic molecular signatures of endocrine disorders such as Cushing’s syndrome, underscoring the power of transcriptome-driven risk stratification [36].

The opportunity lies in laboratories becoming interpretation engines, translating these complex data streams into actionable clinical insights through AI-powered analytics and federated learning models that protect privacy while enabling global collaboration. Yet challenges remain including data interoperability, standardization, clinical validation, and cost, all of which continue to hinder widespread adoption.

The roadmap toward 2050 will require coordinated action across several dimensions: harmonized international frameworks for multi-omics data exchange and annotation; open-access bioinformatics pipelines designed for deployment in low-bandwidth and low-computational-resource environments; automation-friendly sample preparation workflows that reduce the manual complexity of omics specimen handling; deep integration with electronic health records and imaging systems to enable the contextualized interpretation that gives multi-omics data clinical meaning; and regulatory frameworks that can evaluate and approve composite multi-omics biomarker panels with the same rigor currently applied to individual analyte assays. Artificial intelligence (AI), digital twins, and model-based precision medicine platforms will play a central role. By distilling large-scale omics datasets into a limited set of clinically actionable biomarkers, these approaches will integrate critical molecular signals with physiological data to enable predictive simulations of disease evolution and treatment response, effectively transforming omics into dynamic, real-time biomarkers suitable for widespread clinical adoption. Together, these developments position laboratory medicine as the clinical interface between multi-omics discovery and actionable health intelligence.

Artificial intelligence as co-pilot

AI is likely to become an increasingly important co-pilot in laboratory medicine. By 2050, AI may eventually function as a fully accredited diagnostic component, provided that appropriate validation and governance frameworks are established [37–39].

Algorithms will assist in quality control, flag inconsistencies, suggest reflex testing, and provide contextual interpretations in natural language for both clinicians and patients. Autonomous decision loops will emerge, enabling AI to initiate confirmatory analyses or highlight potential errors, but human oversight will remain the ultimate safeguard [40–42]. The power of AI will be in augmentation, not substitution: laboratory professionals will supervise, interpret, and guide these systems, ensuring that empathy and clinical reasoning complement computation.

Agentic AI systems, capable of autonomous goal-directed actions across complex workflows, may further enhance laboratory operations by coordinating analytical, logistical, and interpretive tasks. However, their deployment will require robust oversight, transparency, and accountability mechanisms [40, 43]. However, challenges around transparency, bias, and regulatory governance will persist. Building trust will demand auditable AI, ethical algorithms, and ongoing education of professionals in digital literacy. The transformation will hinge on redefining accreditation systems to include “AI-as-an-assay” certification, ensuring performance traceability like instrument calibration. By embracing AI as a partner rather than a tool, laboratories will gain efficiency and insight, allowing experts to focus on complex decision-making and the human dimensions of care. In this human–machine alliance, intelligence becomes collective, continuous, and deeply connected to patient value. AI will augment rather than replace laboratory professionals. Future deployment will depend on transparent governance, continuous validation, and international standards ensuring safety, interoperability, and trust.

Distributed and virtual hospitals

The boundaries of hospitals may progressively extend beyond traditional buildings toward homes, communities, and digital environments. By 2050, laboratory medicine will operate at the center of this distributed ecosystem, connecting point-of-care diagnostics, wearable biosensors, and telemedicine platforms into a continuous feedback loop of data and care [44, 45].

Blood testing, microbiology, and metabolic monitoring will happen in pharmacies, workplaces, and homes. This

shift will be underpinned by the maturation of autonomous home-sampling technologies, moving beyond invasive venipuncture to painless, user-friendly microsampling [46]. Emerging home-based diagnostic technologies, including passive monitoring systems such as smart toilets, may support continuous health monitoring and earlier disease detection [47]. All results will be validated in real time by central laboratories acting as quality assurance hubs.

Virtual hospitals will combine remote diagnostics with predictive analytics, allowing clinicians to monitor biochemical changes before symptoms appear. The potential is enormous: reduced hospitalizations, personalized care trajectories, and cost-effective population health management. Yet the challenge lies in harmonizing quality across decentralized settings. Ensuring traceability, interoperability, and cybersecurity will require shared calibration frameworks and robust digital infrastructure. Laboratories may progressively evolve into connected intelligence networks, bridging citizens, clinicians, and data systems through continuous validation and interpretation. Distributed diagnostics could extend laboratory medicine beyond hospital walls while preserving centralized quality assurance and clinical oversight.

Patient-owned data and biomarker passports

In 2050, patients will no longer be passive recipients of results; they will be the primary owners of their health data. Empowered by interoperable digital standards such as Fast Healthcare Interoperability Resources (FHIR) and secured through blockchain, individuals will carry lifelong biomarker passports that consolidate all laboratory, imaging, and wearable data into a single, secure ecosystem. This shift from institutional to personal data sovereignty will revolutionize how diagnostics are shared, interpreted, and applied. Each citizen will have the ability to control consent dynamically, granting healthcare providers, insurers, or researchers temporary and transparent access to their datasets. This democratization of data will enhance personalization, continuity of care, and participation in population health initiatives. Laboratories will transition from data controllers to trusted data stewards, ensuring traceability, integrity, and ethical use. The main obstacles will include digital literacy, regulatory heterogeneity, and cross-border data governance. Addressing these challenges requires global harmonization of consent models and educational initiatives empowering citizens to understand and manage their digital health identity. In the future, the patient’s digital twin and biomarker passport will serve as

living health ledgers, bridging personal autonomy with public good and making laboratory medicine a truly participatory science.

Consumerization of health and digital twins

The convergence of healthcare, consumer technology, and AI will blur the boundary between medical diagnostics and personal well-being. By 2050, many individuals may participate in digital health ecosystems supported by validated biosensors and personalized health platforms [48–51].

This twin will simulate real-time biological processes, predict responses to lifestyle or therapy adjustments, and help prevent disease long before symptoms arise. The consumerization of health will empower citizens to actively manage their wellness but will also demand rigorous validation and ethical oversight to prevent inequities and misinformation. Laboratories will ensure that data from wearables and consumer devices meet analytical and clinical standards, linking convenience with credibility. Digital twins could integrate laboratory biomarkers, omics data, and imaging into dynamic physiological models capable of testing millions of therapeutic scenarios. Such predictive simulations will turn health management into a collaborative process between individual, clinician, and machine. Yet transparency, data protection, and model explainability will remain non-negotiable. Validated consumer-generated data could progressively complement conventional laboratory testing within preventive care pathways.

Imaging, theranostics and cross-disciplinary convergence

Laboratory medicine will no longer operate in isolation but as part of a unified diagnostic-theranostic ecosystem. By 2050, radiomics, molecular imaging, and biochemical assays may increasingly converge into integrated data streams that guide real-time therapy [52–55].

A patient's tumor, for instance, will be monitored simultaneously through circulating biomarkers, imaging signatures, and genomic alterations, allowing clinicians to adjust targeted treatments dynamically. This convergence of disciplines could transform laboratories into central nodes of multimodal intelligence, harmonizing molecular, morphological, and functional data. The fusion of laboratory and imaging sciences will enhance precision in oncology, infection control, and critical care, making diagnostics inseparable from therapeutics. The primary barriers will be siloed infrastructures, differing reimbursement frameworks, and

professional boundaries that separate laboratory and imaging specialties. Overcoming these divisions will require interoperable data standards, shared educational pathways, and multidisciplinary governance models. The convergence of laboratory medicine and imaging may progressively redefine precision diagnostics through integrated multimodal interpretation [56, 57].

Mass prevention and planetary health

Laboratory medicine may progressively extend its mission beyond individual diagnostics toward population and planetary health. The global rise in cardiometabolic, infectious, and environmental diseases will demand that laboratories operate as sentinels of planetary health [11, 19]. Targeted or population-level screening for NT-proBNP, Lp(a), kidney markers, and inflammatory mediators could support earlier detection of chronic conditions at scale. Simultaneously, laboratories will monitor the health of the environment through wastewater epidemiology, air biosensing, and biodiversity tracking, providing early warnings for pandemics, antimicrobial resistance, or pollution-related illnesses. This integration of “One Health” principles will link human biology with environmental stewardship [19, 27]. The challenge will be securing political and financial alignment for preventive programs, as well as integrating diverse datasets into coherent public-health dashboards. Laboratories may increasingly collaborate with governments, NGOs, and climate agencies, adopting sustainability indicators within their own operations. Success will increasingly be measured by disease prevented rather than tests performed.

Regenerative medicine, gene editing and advanced therapeutic monitoring

By 2050, laboratory medicine may extend beyond diagnosis toward enabling, monitoring, and optimizing advanced therapies. Regenerative medicine, gene editing, synthetic biology, and cell-based therapies will increasingly rely on laboratory expertise throughout the therapeutic lifecycle.

Laboratories will characterize therapeutic products, validate molecular interventions, monitor treatment efficacy, detect off-target effects, and provide longitudinal surveillance using cell-free DNA, single-cell immune profiling, proteomics, metabolomics, and digital biomarkers.

Artificial intelligence and digital twins may integrate these multidimensional datasets to predict therapeutic

response, optimize treatment selection, and anticipate complications before clinical manifestations occur.

Delivering this vision will require harmonized analytical standards, long-term surveillance strategies, equitable access, and internationally coordinated regulatory frameworks. Laboratory medicine will progressively evolve from supporting therapeutic decisions toward becoming an integral component of precision therapeutic management.

Resilient and sustainable laboratories

Sustainability and resilience are likely to become dual imperatives of 2050 laboratories. The environmental impact of diagnostics, from reagent waste to energy use, will drive a profound shift toward circular, carbon-neutral operations [28]. Laboratories will employ renewable micro-grids, recyclable consumables, and AI-optimized workflows that minimize idle energy consumption. Sustainability may become a core performance indicator, progressively integrated into accreditation systems alongside analytical quality. At the same time, resilience will take on a broader meaning: laboratories will serve as early-warning nodes for health crises, climate emergencies, and antimicrobial resistance. Digital infrastructure will enable rapid reconfiguration in response to outbreaks or supply disruptions. The rise of micro-sampling, enabled by advanced automation, will significantly reduce sample volumes and reagent waste, contributing to a greener laboratory footprint. The major barriers will include upfront investment costs, fragmented green standards, and limited policy incentives. The path forward involves embedding sustainability in procurement, leveraging digital twins for energy modeling, and establishing global laboratory sustainability benchmarks. A resilient laboratory in 2050 will thus embody not only scientific precision but ecological intelligence, a model of how healthcare can thrive within planetary limits.

Laboratory medicine as Industry 5.0

The laboratory workforce will undergo a complete renaissance by 2050. Automation and AI will not eliminate jobs but transform them, creating demand for hybrid professionals fluent in biomedicine, informatics, ethics, and sustainability [58–61].

Academic medicine will pivot from volume to value, rewarding translational impact, innovation, and societal relevance rather than publication counts [62]. Education will evolve toward adaptive, lifelong learning ecosystems where simulation, immersive technologies, and AI tutors

continuously reskill professionals. Laboratories will become living classrooms, integrating research, diagnostics, and patient interaction in real time. Yet cultural resistance and rigid institutional hierarchies remain obstacles. Leadership will need to foster inclusion, creativity, and purpose, ensuring that the next generation views laboratory medicine not as technical work but as an essential societal mission. The academic laboratory of 2050 will blend science, empathy, and design, producing professionals capable of guiding the ethical and sustainable transformation of healthcare. In this new era, excellence will be defined not only by knowledge but by its positive impact on human and planetary well-being.

The future laboratory will be a living ecosystem in which robots, algorithms, and humans work side by side. Instead of automation designed to increase throughput, the focus will be on augmentation, amplifying human intelligence and creativity [5, 60, 61]. Collaborative robots (cobots) will handle repetitive, ergonomic, or hazardous steps, freeing laboratory professionals to concentrate on clinical dialogue and interpretation. Gesture- and voice-based interfaces will make communication with analytical platforms natural and intuitive. Digital twins, virtual replicas of instruments or even whole laboratories, will allow continuous optimization, remote troubleshooting, and scenario testing without disrupting real-world operations.

By 2050, many analytical processes may operate within human-machine partnerships combining automation, standardization, contextual interpretation, and ethical oversight. This balanced approach will also contribute to workforce satisfaction, reducing burnout linked to monotonous validation tasks [61].

Industry 5.0 will thus mark the transition from “automated” to “aware” laboratories, systems that learn, adapt, and collaborate. In this vision, technology becomes a trusted colleague rather than a replacement, enabling laboratories to deliver precision with a human touch while advancing sustainability and resilience.

Automation in laboratory medicine will extend beyond high-volume chemistry to include multi-omics workflows: automated extraction, nucleic acid handling, mass spectrometry, and spatial omics data capture [29, 30].

Beyond technological transformation, the future of laboratory medicine will depend on the evolution of its professionals. Laboratory specialists may progressively transition from analytical experts toward clinical intelligence consultants, combining expertise in biomarker science, artificial intelligence, systems medicine, sustainability, implementation science, and patient communication. Training programs will increasingly integrate data science, digital health, ethics, health economics, regulatory science,




Figure 2: The laboratory professional of 2050: orchestrating health intelligence. The role of laboratory professionals will progressively evolve from analytical expertise toward health intelligence leadership. Beyond biomarker science, future competencies will encompass artificial intelligence and data science, clinical consultation, ethics and governance, sustainability leadership, and systems thinking. Together, these complementary capabilities will enable laboratory professionals to transform biological data into trusted intelligence supporting predictive, preventive, personalized, equitable, and sustainable healthcare.

and leadership alongside traditional laboratory medicine. Future laboratory professionals may therefore become orchestrators of health intelligence rather than custodians of analytical platforms (Figure 2).

Taken together, these ten megatrends (Table 1) should not be viewed as independent developments. Rather, they represent interconnected forces that may collectively reshape laboratory medicine into a more predictive, personalized, preventive, participatory, and sustainable discipline. The extent and pace of adoption will vary across regions, healthcare systems, and regulatory environments, creating multiple possible pathways toward 2050.

Scenarios for 2050

Exploring alternative futures provides a structured framework for anticipating uncertainty and supporting strategic preparedness. The four scenarios presented below are not predictions but plausible narratives illustrating how different combinations of technological innovation, societal priorities, regulatory evolution, and environmental pressures may shape laboratory medicine by 2050 (Figure 3). Rather than representing mutually exclusive futures, these scenarios highlight complementary pathways that may coexist across different healthcare systems and geographical contexts.

The hyper-intelligent laboratory

By 2050, the laboratory may evolve into a continuously learning health intelligence ecosystem where artificial intelligence, advanced automation, and distributed diagnostics operate as an integrated whole. Rather than functioning solely as high-throughput analytical facilities, laboratories could progressively become cognitive platforms capable of combining biological, clinical, imaging, and environmental information into real-time decision support [28]. Analytical workflows would increasingly be coordinated by AI, optimizing sample routing, quality assurance, resource utilization, and contextual interpretation. Laboratory reports may evolve from static numerical outputs into dynamic clinical intelligence integrating longitudinal biomarker trajectories, multimodal data, and individualized risk prediction. Continuous quality monitoring, predictive maintenance, and digital twins of laboratory operations could further improve efficiency, resilience, and analytical reliability. Despite increasing autonomy, human expertise will remain indispensable. Laboratory professionals will increasingly supervise AI systems, ensure interpretability, oversee governance, and maintain responsibility for ethical and clinical decision-making. The successful implementation of this scenario will depend on robust validation frameworks, cybersecurity, interoperability standards, and international regulatory coordination. Rather than

Table 1: Ten megatrends in laboratory medicine: drivers, opportunities, and implications for 2050.

Megatrend	Key Drivers	Opportunities by 2050	Main Challenges/Barriers	Strategic Implications
Precision Diagnostics & Integrated Multi-Omics	Advances in sequencing, AI analytics, and federated data	Personalized prevention, molecular navigation, multi-layer biomarker panels	Standardization, cost, data interoperability	Global reference frameworks and AI-driven interpretation pipelines
Artificial Intelligence as Co-Pilot	Generative & agentic AI, explainable algorithms	Continuous quality validation, predictive analytics	Bias, trust, ethical governance	Certification of “AI-as-an-assay” and professional AI literacy
Distributed & Virtual Hospitals	Telemedicine, POCT, connected devices	Continuous care, early intervention, decentralized testing	Data security, calibration, reimbursement	Hybrid laboratory networks and real-time QA frameworks
Patient-Owned Data & Biomarker Passports	Blockchain, FHIR interoperability, digital ethics	Citizen empowerment, global data portability	Regulation diversity, digital divide	Dynamic consent and patient co-design of pathways
Consumerisation & Digital Twins	Wearables, metabolic sensors, simulation models	Continuous monitoring, proactive prevention	Validation, model explainability	Integration of laboratory data into digital twins
Imaging & Theranostics	Radiomics, molecular imaging, AI convergence	Unified diagnostic-therapeutic platforms	Siloed reimbursement, training gaps	Cross-disciplinary training and shared data hubs
Mass Prevention & Planetary Health	Climate change, chronic diseases, One Health agenda	Population screening and environmental biomonitoring	Funding, governance, data fusion	Laboratory-driven health surveillance systems
Regenerative & cell therapies	Bioprinting, cell engineering, omics monitoring	Personalized graft analytics, immune modeling	Cost, ethical acceptance	Standardized reference panels and real-time graft analytics
Resilient & Sustainable Labs	Climate policies, green innovation	Net-zero diagnostics, health-security resilience	Investment, green standards gap	Sustainability metrics in accreditation
Academic Medicine & Workforce	Automation, digitalization, ethics	Hybrid professional roles, societal impact metrics	Institutional inertia	Interdisciplinary curricula and “learning laboratories”

Ten megatrends will shape laboratory medicine by 2050, driven by converging advances in technology, sustainability, and human-centered design, with key opportunities and barriers across domains such as multi-omics, AI, and planetary health. Together, they redefine laboratories as decentralized health intelligence networks enabling prevention, personalization, and population well-being.




Figure 3: Four exploratory scenarios for laboratory medicine in 2050. The figure summarizes four complementary scenarios for laboratory medicine in 2050: the Hyper-Intelligent Laboratory, the Sustainable and Regenerative Laboratory, the Patient-in-the-Loop Revolution, and the Spacefaring Laboratory. These scenarios illustrate alternative but potentially coexisting trajectories shaped by technology, environmental priorities, patient participation, and extreme-environment innovation. They are intended as strategic foresight tools rather than predictions.

replacing laboratory medicine, artificial intelligence may ultimately amplify its value, transforming laboratories into trusted intelligence hubs supporting predictive, preventive, and personalized healthcare.

The sustainable and regenerative laboratory

By 2050, sustainability may become as fundamental to laboratory excellence as analytical quality. Future laboratories could progressively evolve into regenerative healthcare ecosystems integrating environmental stewardship, resource efficiency, and diagnostic innovation. Renewable energy systems, circular reagent management, recyclable consumables, and AI-assisted optimization of laboratory workflows may substantially reduce the environmental footprint of diagnostic services [20, 28]. Sustainability metrics could become integrated into accreditation frameworks alongside conventional indicators of analytical performance. Beyond their own operations, laboratories may increasingly contribute to planetary health through environmental surveillance, wastewater epidemiology, antimicrobial resistance monitoring, and biodiversity assessment, supporting One Health initiatives that recognize the interdependence of human, animal, and environmental health.

Although important challenges remain, including investment costs, global inequalities, and the lack of harmonized sustainability standards, this scenario illustrates how laboratory medicine could simultaneously improve patient outcomes while contributing to environmental resilience. Future laboratory excellence may therefore be measured not only by diagnostic accuracy, but also by long-term societal and planetary impact.

The patient-in-the-loop revolution

By 2050, patients may become active participants in laboratory medicine rather than passive recipients of diagnostic information. Supported by interoperable biomarker passports, validated wearable technologies, and AI-assisted interpretation, individuals could increasingly contribute to continuous health monitoring and personalized prevention [26, 38, 63]. Laboratory reports may evolve into interactive decision-support platforms integrating longitudinal biomarker data, clinical context, and patient-generated information. Shared digital environments could facilitate collaborative decision-making among patients, clinicians, and laboratory professionals, improving engagement, adherence, and preventive care. This transformation would also reposition laboratories as trusted stewards of health

information, ensuring analytical quality, data integrity, and equitable interpretation across increasingly decentralized healthcare systems. Success, however, will depend on digital literacy, transparent governance, robust privacy protection, and equitable access to digital health technologies. Ultimately, this scenario emphasizes that the future of laboratory medicine is not only technological but also profoundly human, strengthening partnerships between citizens, healthcare professionals, and intelligent diagnostic systems.

The spacefaring laboratory

Although more speculative than the preceding scenarios, the Spacefaring Laboratory explores how extreme operational environments may accelerate innovations relevant to terrestrial healthcare. Long-duration space missions would require highly autonomous diagnostic systems capable of operating with minimal human intervention, limited resources, and delayed communication with Earth [65]. Miniaturized laboratories, advanced biosensors, microfluidic technologies, and AI-supported diagnostics developed for lunar or Martian habitats may ultimately improve resilience, portability, and sustainability within conventional healthcare systems. Its primary relevance is terrestrial: the scenario provides a stress test for diagnostics in remote communities, disaster response, military medicine, and other resource-constrained environments on Earth. While human settlement beyond Earth remains uncertain, technologies developed for space exploration may influence the future evolution of laboratory medicine by improving autonomy, robustness, and accessibility.

Although more speculative than the preceding scenarios, the Spacefaring Laboratory explores how extreme operational environments may accelerate innovations relevant to terrestrial healthcare. Long-duration space missions will require highly autonomous diagnostic systems capable of operating with minimal human intervention, limited resources, and delayed communication with Earth [64]. Miniaturized laboratories, advanced biosensors, microfluidic technologies, and AI-supported diagnostics developed for lunar or Martian habitats may ultimately improve resilience, portability, and sustainability within conventional healthcare systems. These technologies could subsequently benefit remote communities, disaster response, military medicine, and other resource-constrained environments on Earth [65]. This scenario illustrates that laboratory innovation is often driven by the most demanding operational challenges. While human settlement beyond Earth remains uncertain, technologies developed for space exploration may substantially influence the future evolution of

laboratory medicine by improving autonomy, robustness, and accessibility.

Taken together, these four scenarios illustrate complementary rather than competing futures. Elements of each are likely to emerge simultaneously across different regions, healthcare systems, and clinical contexts. Their purpose is not to predict a single endpoint, but to stimulate strategic thinking about how laboratory medicine can responsibly harness technological innovation while preserving scientific rigor, equity, sustainability, and patient-centered care.

Navigating the road to 2050: shared responsibilities

The transformation of laboratory medicine toward health intelligence will not occur automatically. It will depend on coordinated actions by scientific societies, healthcare professionals, industry, academia, regulators, policymakers, and patients. While the pace of adoption will differ across healthcare systems, several strategic priorities are likely to be universally important.

First, innovation must remain clinically meaningful. Emerging technologies – including artificial intelligence, multi-omics, decentralized diagnostics, and digital health – should be evaluated not only for analytical performance but also for their impact on clinical decision-making, patient outcomes, cost-effectiveness, and healthcare sustainability. Future validation frameworks will therefore need to extend beyond analytical accuracy toward continuous assessment of real-world performance.

Second, governance must evolve alongside innovation. Distributed laboratory medicine will require harmonized international standards integrating analytical validation, AI performance monitoring, interoperability certification, cybersecurity, post-market surveillance, and human oversight. International organizations such as IFCC, ISO, CLSI, and regulatory authorities will play complementary roles in developing trusted governance frameworks capable of supporting safe and equitable implementation across healthcare systems.

Third, the laboratory workforce must evolve. Future laboratory professionals will require competencies extending beyond analytical sciences to include artificial intelligence, digital health, implementation science, ethics, sustainability, health economics, communication, and systems leadership. Education should progressively shift from episodic training toward lifelong competency development capable of supporting continuous technological evolution.

Fourth, innovation must remain globally inclusive. The future described in this paper should not be viewed exclusively through the perspective of high-income healthcare systems. Affordable point-of-care testing, interoperable digital platforms, cloud-based diagnostics, and AI-assisted interpretation have the potential to substantially improve access to high-quality laboratory medicine in low- and middle-income countries. Achieving this objective will require equitable financing, workforce development, locally relevant validation strategies, and sustainable digital infrastructure.

Finally, collaboration will become the defining characteristic of laboratory medicine. The future laboratory will increasingly operate within interconnected ecosystems involving clinicians, patients, engineers, data scientists, industry, public health authorities, and policymakers. Scientific excellence alone will no longer be sufficient; progress will depend equally on interoperability, transparency, trust, and shared responsibility.

The vision presented in this paper should therefore be considered neither a prediction nor a technological roadmap, but a framework for strategic reflection. By anticipating emerging opportunities and challenges today, the laboratory community can actively shape a future in which innovation, scientific rigor, equity, and sustainability evolve together, enabling laboratory medicine to become a trusted foundation of global health intelligence.

Conclusions

Laboratory medicine is entering a transition from analytical testing toward trusted health intelligence. Although the future described here remains uncertain, the convergence of artificial intelligence, multi-omics, distributed diagnostics, sustainability, and patient-centered care offers an opportunity to redefine the contribution of laboratory medicine to healthcare. Achieving this vision will require scientific innovation, responsible governance, equitable implementation, and a workforce prepared to lead this transformation. Rather than predicting the future, this paper proposes a framework to stimulate strategic reflection and guide the evolution of laboratory medicine over the coming decades.

Research ethics: Not applicable.

Informed consent: Not applicable.

Author contributions: All authors have accepted responsibility for the entire content of this manuscript and approved its submission.

Use of Large Language Models, AI and Machine Learning Tools: None declared.

Conflict of interest: The authors state no conflict of interest. Several co-authors are employed by diagnostic companies. This employment had no influence on the conception or conclusions of this vision paper.

Research funding: None declared.

Data availability: Not applicable.

References

- Horton S, Wilson ML, Cheung ANY, DeStigter K, Kohli M, Sayed S, et al. Moving the dial on diagnostics: an update from the Lancet Commission on diagnostics. *Lancet* 2025;405:2241–54.
- Lippi G, Plebani M. Reshaping laboratory medicine through technological advances. *Clin Chem Lab Med* 2026;64(4):749–51. <https://doi.org/10.1515/CCLM-2025-1733>.
- Greaves RF, Bernardini S, Ferrari M, Fortina P, Gouget B, Gruson D, et al. Key questions about the future of laboratory medicine in the next decade of the 21st century: A report from the IFCC-Emerging Technologies Division. *Clin Chim Acta* 2019;495:570–89.
- What will a healthcare system in 2050 look like? 2050. <https://assets.kpmg.com/content/dam/kpmgsites/uk/pdf/2024/04/what-will-a-healthcare-system-in-2050-look-like.pdf>.
- Imamguluyev R. Artificial Intelligence 2050: Predictions, Challenges, and Innovations. *Int J Res Publ Review* 2024;5:2933–45.
- Saxena S, O’Ryan M, Baum F. Vision 2050: a revolution in academic medicine for better health for all. *BMJ* 2025;389. <https://doi.org/10.1136/BMJ.R561>.
- Nichols E, Steinmetz JD, Vollset SE, Fukutaki K, Chalek J, Abd-Allah F, et al. Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the Global Burden of Disease Study 2019. *Lancet Public Health* 2022;7:e105–25.
- Chong B, Jayabaskaran J, Jauhari SM, Chan SP, Goh R, Kueh MTW, et al. Global burden of cardiovascular diseases: projections from 2025 to 2050. *Eur J Prev Cardiol* 2025;32(11):1001–15.
- The metabolic health revolution has arrived | McKinsey n.d. <https://www.mckinsey.com/mhi/our-insights/the-path-toward-a-metabolic-health-revolution> (Accessed January 28, 2026).
- Joynt Maddox KE, Elkind MSV, Aparicio HJ, Commodore-Mensah Y, de Ferranti SD, Dowd WN, et al. Forecasting the Burden of Cardiovascular Disease and Stroke in the United States Through 2050-Prevalence of Risk Factors and Disease: A Presidential Advisory From the American Heart Association. *Circulation* 2024;150:e65–88.
- Chong B, Jayabaskaran J, Jauhari SM, Chan SP, Goh R, Kueh MTW, et al. Global burden of cardiovascular diseases: projections from 2025 to 2050. *Eur J Prev Cardiol* 2024. <https://doi.org/10.1093/EURJPC/ZWAE281>.
- Fu W, Ho PCL. Blood-based biomarkers for Alzheimer’s disease: Advances in early detection and monitoring of age-related neurodegeneration. *Ageing Res Rev* 2026;117. <https://doi.org/10.1016/j.arr.2026.103058>.
- Bizuayehu HM, Ahmed KY, Kibret GD, Dadi AF, Belachew SA, Bagade T, et al. Global Disparities of Cancer and its Projected Burden in 2050. *JAMA Netw Open* 2024;7:e2443198.
- Shen C, Cai C, Zhang Y, Xu H, Wu Y, Xu T, et al. Global burden of colorectal cancer and associated risk factors in young-older adults: trends from 1990 to 2021 with projections to 2050. *Medicine* 2026;105:e47448.
- Lenoci D, Moresco E, Cavalieri S, Bergamini C, Torchia E, Botta L, et al. Oral cancer in young adults: incidence, risk factors, prognosis, and molecular biomarkers. *Front Oncol* 2024;14. <https://doi.org/10.3389/FONC.2024.1452909>.
- Schnabel-Besson E, Mütze U, Dikow N, Hörster F, Morath MA, Alex K, et al. Wilson and Jungner Revisited: are Screening Criteria Fit for the 21st Century? *Int J Neonatal Screen* 2024;10:62.
- Nakar-Weinstein A, Ben-Moshe Y, Sutton RR. From PKU to Genome Sequencing: the Past, Present, and Future of Newborn Screening. *Clin Chem* 2025;72:123–32.
- Dyikanov D, Zaitsev A, Vasileva T, Wang I, Sokolov AA, Bolshakov ES, et al. Comprehensive peripheral blood immunoprofiling reveals five immunotypes with immunotherapy response characteristics in patients with cancer. *Cancer Cell* 2024;42:759–79.e12.
- Naghavi M, Vollset SE, Ikuta KS, Swetschinski LR, Gray AP, Wool EE, et al. Global burden of bacterial antimicrobial resistance 1990–2021: a systematic analysis with forecasts to 2050. *Lancet* 2024;404:1199–226.
- Reddy BVJSB. WORLD 2050 : THE NEW ECONOMIC ORDER. 2025. <https://doi.org/10.2139/SSRN.5295054>.
- Münzel T, Lüscher T, Kramer CM, Churchwell K, Mbakwem A, Rajagopalan S. Environmental stressors and cardiovascular health: acting locally for global impact in a changing world: a statement of the European Society of Cardiology, the American College of Cardiology, the American Heart Association, and the World Heart Federation. *Eur Heart J* 2026;47(15):1782–9.
- Maunder B. An ounce of prevention is worth a pound of cure: the role for international law in preventing pandemics | Australian International Law Journal n.d. <https://search.informit.org/doi/10.3316/agispt.20220908073832> (Accessed January 27, 2026).
- Ng M, Gakidou E, Lo J, Abate YH, Abbafati C, Abbas N, et al. Global, regional, and national prevalence of adult overweight and obesity, 1990–2021, with forecasts to 2050: a forecasting study for the Global Burden of Disease Study 2021. *Lancet* 2025;405:813–38.
- What will the global economy look like in 2050? | Capital Economics n.d. <https://www.capitaleconomics.com/what-will-global-economy-look-2050> (Accessed January 28, 2026).
- Jamison DT, Summers LH, Chang AY, Karlsson O, Mao W, Norheim OF, et al. Global health 2050: the road to halving premature death by mid-century. *Lancet* 2024;404:1561.
- Chen C, Wang J, Pan D, Wang X, Xu Y, Yan J, et al. Applications of multi-omics analysis in human diseases. *MedComm* 2023;4:e315.
- Gruson D, Fux E, Kemaloğlu ÖZ T, Gouget B, Lee W, Shah S, et al. Contribution of laboratory medicine and emerging technologies to cardiovascular risk reduction via exposome analysis: an opinion of the IFCC Division on Emerging Technologies. *Clin Chem Lab Med* 2024;63:521–4.
- Giesriegl F, Mrazek C, Cadamuro J. How laboratory medicine will change in the near future: integrating artificial intelligence, automation, and human expertise in the era of Industry 5.0. *J Lab Precis Med* 2025;10. <https://doi.org/10.21037/jlpm-25-6>.
- Gottardi Zamperla M, Barbi V, Negri S, Atlante S, Gaetano C. Omics medicine: what the clinicians should know. *Eur J Intern Med* 2026;148. <https://doi.org/10.1016/J.EJIM.2026.106759>.

30. Biswas S, Acharya S, Prajapat A, Sen P, Desai S, Giri S, et al. Integrating multi-omics data for next-generation cancer research and precision medicine. *Clin Transl Oncol* 2026. <https://doi.org/10.1007/S12094-026-04368-8>.
31. Nam Y, Park H-D. Revolutionizing Laboratory Practices: Pioneering Trends in Total Laboratory Automation. *Ann Lab Med* 2025;45. <https://doi.org/10.3343/ALM.2024.0581>.
32. Zima T, Plebani M. Automation in value-based laboratory medicine: driving precision, capacity, and better outcomes. *Clin Chem Lab Med* 2026;64(6):1197–200. <https://doi.org/10.1515/CCLM-2026-0023>.
33. Yang P, Zeng J, Li L, Ma R, Peng J, Zhou W, et al. From Cas proteins to cutting-edge biosensors: a new era in clinical pathogen diagnostics. *J Infect* 2025;91. <https://doi.org/10.1016/J.JINF.2025.106526>.
34. Liu Y, Dai Y, Wang L. Spatial omics at the forefront: emerging technologies, analytical innovations, and clinical applications. *Cancer Cell* 2026;44:24–49.
35. Zhang L, Chen D, Song D, Liu X, Zhang Y, Xu X, et al. Clinical and translational values of spatial transcriptomics. *Signal Transduct Targeted Ther* 2022;7:111.
36. Birtolo MF, Armignacco R, Benanteur N, Baussart B, Villa C, De Murat D, et al. Whole blood transcriptomic signature of Cushing's syndrome. *Eur J Endocrinol* 2024;191:55–63.
37. Meskó B, Hetényi G, Györfy Z. Will artificial intelligence solve the human resource crisis in healthcare? *BMC Health Serv Res* 2018;18:545.
38. Mesko B. The promise of the metaverse in cardiovascular health. *Eur Heart J* 2022;43:2647–9.
39. Bartusik-Aebischer D, Raj DRJ, Aebischer D. Artificial Intelligence in Medical Diagnostics: Foundations, Clinical Applications, and Future Directions. *Appl Sci* 2026, Vol 16, 2026:728.
40. Gruson D, Gouget B, Lee W, Greaves R, Liu Y, Ebert S, et al. From automation to agentic artificial intelligence in laboratory medicine: an opinion of the IFCC Division on Emerging Technologies. *Clin Chem Lab Med* 2025;64(5):985–8. <https://doi.org/10.1515/CCLM-2025-1314>.
41. Meder B, Asselbergs FW, Ashley E. Artificial intelligence to improve cardiovascular population health. *Eur Heart J* 2025;46:1907–16.
42. Ferber D, Hilgers L, Höper C, Kinny-Köster B, Eckardt JN, Egger-Heidrich K, et al. Towards autonomous medical artificial intelligence agents. *Nature* 2026;1–10. <https://doi.org/10.1038/s41586-026-10675-5>.
43. Lakhan SE. The Agentic Era: Why Biopharma Must Embrace Artificial Intelligence That Acts, Not Just Informs *Cureus* 2025;17:e83390.
44. Global Wearable Health Tech Use May Rise 42-Fold by 2050: study. n.d. <https://www.digitalhealthnews.com/global-use-of-wearable-health-tech-could-rise-42-fold-by-2050-study-finds> (Accessed January 31, 2026).
45. Zendeabad SA, Ghasemi J, Khodadad FS. Trustworthy AI in Telehealth: Navigating Challenges, Ethical Considerations, and future opportunities for Equitable. *Healthcare Technol Lett* 2025;12:e70020.
46. Spooner N, Baker D, Carling RS, Collier BB, Gong P, Maroto-García J, et al. Patient centric blood sampling and analysis for diagnostics and laboratory medicine. *Bioanalysis* 2025;17:1283–93.
47. Ge TJ, Rahimzadeh VN, Mintz K, Park WG, Martinez-Martin N, Liao JC, et al. Passive monitoring by smart toilets for precision health. *Sci Transl Med* 2023;15. <https://doi.org/10.1126/SCITRANSLMED.ABK3489>.
48. Saratkar SY, Langote M, Kumar P, Gote P, Weerarathna IN, Mishra GV. Digital twin for personalized medicine development. *Front Digit Health* 2025;7:1583466.
49. Thangaraj PM, Benson SH, Oikonomou EK, Asselbergs FW, Khera R. Cardiovascular care with digital twin technology in the era of generative artificial intelligence. *Eur Heart J* 2024;45:4808–21.
50. Mwogosi A, Mambile C. Digital ecosystems for healthcare communication and collaboration: a scoping review. *Digit Health* 2025;11:20552076251377932.
51. Ait LA, Rajendran J, Slaughter G. Advances and challenges in digitally connected point-of-care biosensing. *Biosens Bioelectron X* 2026;28:100728.
52. Wu X, Dai W. Beyond imaging: integrating radiomics, genomics, and Multi-Omics for Precision Breast Cancer Management. *Cancers (Basel)* 2025;17:3408.
53. Cheng CH, Shi SS. Artificial intelligence in cancer: applications, challenges, and future perspectives. *Mol Cancer* 2025;24:274.
54. Ligerio M, Gielen B, Navarro V, Cresta Morgado P, Prior O, Dienstmann R, et al. A whirl of radiomics-based biomarkers in cancer immunotherapy, why is large scale validation still lacking? *Npj Precis Oncol* 2024;8:42.
55. Flaiban E, Orhan K, Gonçalves BC, Lopes SLPC, Costa ALF. Radiomics in Action: Multimodal Synergies for Imaging Biomarkers. *Bioengineering* 2025;12:1139.
56. Mani S, Lalani SR, Pammi M. Genomics and multiomics in the age of precision medicine. *Pediatr Res* 2025;97:1399–410.
57. Lippi G, Plebani M. Integrated diagnostics: the future of laboratory medicine? *Biochem Med (Zagreb)* 2020;30. <https://doi.org/10.11613/BM.2020.010501>.
58. Zirar A, Ali SI, Islam N. Worker and workplace artificial intelligence (AI) coexistence: emerging themes and research agenda. *Technovation* 2023;124:102747.
59. What role for AI skills in (re-)shaping the future European workforce? 2025:765806. https://www.europarl.europa.eu/thinktank/en/document/EPRS_BRI.
60. Invest in the workforce for the AI age: a blueprint for scale, skills and responsible growth | World Economic Forum n.d. <https://www.weforum.org/stories/2026/01/ai-roadmap-transforming/> (Accessed January 31, 2026).
61. Human skills will matter more than ever in the age of AI | McKinsey n.d. <https://www.mckinsey.com/mgi/media-center/human-skills-will-matter-more-than-ever-in-the-age-of-ai> (Accessed January 27, 2026).
62. Plebani M. Advancing value-based laboratory medicine. *Clin Chem Lab Med* 2025;63:249–57.
63. Chen Q, Wu W, Wang K, Han Z, Yang C. Methods for detecting of cardiac troponin I biomarkers for myocardial infarction using biosensors: a narrative review of recent research. *J Thorac Dis* 2023;15:5112–21.
64. Khan MI, Yasmeen T, Khan M, Hadi NU, Asif M, Farooq M, et al. Integrating industry 4.0 for enhanced sustainability: pathways and prospects. *Sustain Prod Consum* 2025;54:149–89.
65. Niknam N, Akbarialiabad H, Farjoud Kouhanjani M, Kolaparambil Varghese LJ, Berrington de González A, Melin MM, et al. Space Oncology: a Comprehensive Scoping Review. *Wilderness Environ Med* 2025;36:148S–71S.